MIM
DSGN icon

MetLife Investment Management’s Design Therapeutics DSGN Stock Holding History

MetLife Investment Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162K Hold
15,249
– – ﹤0.01% 2329
2025
Q4 		$143K Buy
15,249
+4,929
+48% +$38.6K ﹤0.01% 2439
2025
Q3 		$77.7K Buy
+10,320
New +$51.7K ﹤0.01% 2740
2025
Q2 		– Sell
-18,962
Closed -$73.2K – 2866
2025
Q1 		$73.2K Sell
18,962
-372
-2% -$1.77K ﹤0.01% 2633
2024
Q4 		$119K Hold
19,334
– – ﹤0.01% 2538
2024
Q3 		$104K Buy
+19,334
New +$90.9K ﹤0.01% 2611
2023
Q3 		– Sell
-22,045
Closed -$139K – 2914
2023
Q2 		$139K Hold
22,045
– – ﹤0.01% 2493
2023
Q1 		$127K Hold
22,045
– – ﹤0.01% 2454
2022
Q4 		$226K Hold
22,045
– – ﹤0.01% 2177
2022
Q3 		$369K Buy
22,045
+5,160
+31% +$103K ﹤0.01% 1857
2022
Q2 		$236K Hold
16,885
– – ﹤0.01% 2197
2022
Q1 		$273K Buy
16,885
+6,021
+55% +$92.2K ﹤0.01% 2153
2021
Q4 		$233K Buy
+10,864
New +$187K ﹤0.01% 1962

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's DSGN Position: Q1 2026 in Review

MetLife Investment Management held its Design Therapeutics (DSGN) position steady in Q1 2026 at 15,249 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #2329.

MetLife Investment Management first reported a position in DSGN in Q4 2021 and has held it in 13 quarters since. The position peaked at $369K in Q3 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • MetLife Investment Management held 15,249 shares of Design Therapeutics worth $162K as of Q1 2026.
  • MetLife Investment Management left its Design Therapeutics share count unchanged in Q1 2026.
  • Design Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2329 holding.
  • MetLife Investment Management first reported a position in Design Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • MetLife Investment Management's Design Therapeutics position peaked at $369K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.